Letter to the editor.
作者信息
D'Alessandro Vito, Greco Mario
机构信息
Respiratory Oncology Section - Internal Medicine Department, of Scientific Institute, "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (FG), Italy.
出版信息
J Blood Med. 2012;3:43-4. doi: 10.2147/JBM.S31413. Epub 2012 Aug 3.
Abstract
摘要
相似文献
1
Letter to the editor.
J Blood Med. 2012;3:43-4. doi: 10.2147/JBM.S31413. Epub 2012 Aug 3.
2
Authors' response to letter to the editor, letter to the editor: Authors' response to letter to the editor: Safety concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse events.
Jpn J Nurs Sci. 2020 Jan;17(1):e12310. doi: 10.1111/jjns.12310. Epub 2019 Dec 2.
3
How to write an editorial letter?
Turk J Urol. 2013 Sep;39(Suppl 1):41-3. doi: 10.5152/tud.2013.053.
4
Letter to the Editor - The implications of the professionalization of health promotion in Canada: a response to JR Graham's letter to the editor.
Health Promot Chronic Dis Prev Can. 2017 May;37(5):172-173. doi: 10.24095/hpcdp.37.5.05.
5
Letter to the Editor Re: Author's Response to Letter to the Editor.
Arch Phys Med Rehabil. 2020 Jun;101(6):1096-1097. doi: 10.1016/j.apmr.2019.12.022. Epub 2020 Mar 7.
6
Response Letter to the Editor in Reference to Letter to the Editor about "Does Overall Catastrophic Health Care Expenditure Make Sense"?
Iran J Public Health. 2018 Aug;47(8):1230-1231.
7
How to write a letter to the editor: an author's guide.
J Chiropr Med. 2006 Winter;5(4):144-7. doi: 10.1016/S0899-3467(07)60147-5.
8
Response Letter to the Editor in Reference to Letter to the Editor about "Molecular Characterization of Animal spp. Isolates from Kermanshah, Western Iran".
Iran J Public Health. 2018 Aug;47(8):1210.
9
Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
Eur Urol. 2021 Feb;79(2):e54-e55. doi: 10.1016/j.eururo.2020.11.019. Epub 2020 Nov 26.
10
Letter to the Editor Regarding: Editor-in-Chief Letter "Optimism versus Pessimism: The Choice Is Yours".
World Neurosurg. 2021 Apr;148:234. doi: 10.1016/j.wneu.2021.01.087.
本文引用的文献
1
Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies.
J Blood Med. 2011;2:1-6. doi: 10.2147/JBM.S9648. Epub 2011 Feb 4.
2
Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel.
Adv Ther. 2011 Aug;28(8):684-97. doi: 10.1007/s12325-011-0041-1. Epub 2011 Jul 15.
3
Management of tumor lysis syndrome: need for evidence-based guidelines.
J Clin Oncol. 2008 Dec 1;26(34):5657-8; author reply 5658-9. doi: 10.1200/JCO.2008.19.6030. Epub 2008 Nov 3.
4
Consensus conference on the management of tumor lysis syndrome.
Haematologica. 2008 Dec;93(12):1877-85. doi: 10.3324/haematol.13290. Epub 2008 Oct 6.
5
Modification of a reactive cysteine explains differences between rasburicase and Uricozyme, a natural Aspergillus flavus uricase.
Biotechnol Appl Biochem. 2002 Aug;36(1):21-31. doi: 10.1042/ba20010083.
Zotero 插件